Skip to main content
Journal of Ophthalmic Inflammation and Infection
Download PDF

Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients

Journal of Ophthalmic Inflammation and Infection volume 14, Article number: 44 (2024) Cite this article

Abstract

Introduction

Uncontrolled non-infectious uveitis affecting the posterior segment (NIU-PS) can lead to vision loss due to repeated bouts of inflammation and consequent tissue damage. Patients with chronic NIU-PS who experience recurrent uveitis after being treated with systemic and short-acting local corticosteroids may benefit from the sustained-release 0.18-mg fluocinolone acetonide implant (FAi).

Methods

In this case series, 18 eyes with chronic, recurrent NIU-PS and cystoid macular edema (CME) treated with the 0.18-mg FAi were analyzed retrospectively. Data on patient demographics, clinical history, previous and concomitant treatments for uveitis recurrence, time to and number of uveitis recurrences, intraocular pressure (IOP), central subfield thickness (CST), and visual acuity (VA) were collected and summarized.

Results

A majority of patients (14/15 [93%]) had a history of ocular surgery, largely cataract extraction, and all developed chronic and recurrent NIU-PS and CME. At baseline, patients had a mean age of 72 years (range: 46 to 93), were 53% male, and had a mean duration of NIU-PS of 3 years (range: 1 to 19). Patients were followed for an average of 16.5 months (range: 2 to 42.5 months) post FAi. Eleven of the 18 eyes (61%) had ≥ 5 recurrences of uveitis since diagnosis, with an average time to recurrence of approximately 12 weeks (range: 1 to 27). All eyes treated with the 0.18-mg FAi showed reduced NIU-PS recurrence and visual and anatomical improvement, as measured by VA and CST, respectively. Two eyes had an IOP elevation that was managed with topical therapy, and one eye was treated with topical prednisolone for additional inflammation management. Two eyes required adjunct therapy with short-acting intravitreal corticosteroids at 7 and 16 weeks for NIU-PS recurrence after 0.18-mg FAi insertion.

Conclusion

After receiving the 0.18-mg FAi, eyes with uncontrolled NIU-PS had sustained resolution of CME and inflammation with limited need for supplementary steroid drops or injections and minimal steroid class-specific adverse effects; none required incisional IOP-lowering surgery.

Background

Chronic uveitis can lead to ocular tissue damage and vision loss due to repeated bouts of inflammation [1]. Uveitis is a major cause of visual morbidity among working-age adults (age 20 to 65 years). A study conducted by Durrani et al. showed prolonged visual loss in two-thirds of patients with non-infectious uveitis, with 22% meeting the criteria for legal blindness [2, 3]. Uveitis is typically classified according to primary location of inflammation along the uveal tract [4, 5]. Intermediate, pan-, and posterior uveitis, while less common than anterior uveitis, often require either systemic or intraocular corticosteroid treatment to effectively manage inflammation [1, 6]. Posterior uveitis can affect the choroid and/or the retina, and is the second most common form of uveitis [4, 6], with 67–90% of posterior uveitis cases being non-infectious [7,8,9,10]. Prior ocular surgery is another common cause of acute and chronic uveitis accompanied by macular edema [4, 7]. Non-infectious uveitis affecting the posterior segment (NIU-PS), though not a pre-defined clinical term in the literature, is an umbrella term referring to inflammation affecting the back of the eye (encompassing intermediate, posterior, and panuveitis) of non-infectious origin. This includes, but is not limited to, idiopathic causes, autoimmune conditions, or surgical insults that result in recurrent inflammation of the posterior eye segment [4, 7].

NIU-PS is often managed with systemic corticosteroids, but long-term use of high-dose corticosteroids can be associated with systemic and ocular side effects. Intraocular and periocular corticosteroids reduce systemic exposure and incidence of adverse events by providing adequate concentration of drug at the site of inflammation. Long-acting intraocular implants have the potential to provide extended control of disease and decrease patient burden by reducing the need for repeated injections and the frequency of disease flares, resulting in better overall control of inflammation [11, 12].

Table 1 Baseline characteristics
Full size table

Approved by the United States Food and Drug Administration (FDA), the intravitreal fluocinolone acetonide implant (FAi) is indicated for use in patients with chronic NIU-PS [13]. The safety and efficacy of treating NIU-PS with a low-dose, sustained-release 0.18-mg intravitreal FAi has been demonstrated in randomized, sham injection controlled, double-masked, phase 3 clinical trials (ClinicalTrials.gov identifiers: NCT01694186 and NCT02746991) and in multiple individual case reports [11,12,13,14]. Herein, we report a series of 18 eyes from 15 patients with recurrent NIU-PS and postoperative uveitic cystoid macular edema (CME) that achieved long-term inflammation control when treated with 0.18-mg FAi.

Table 2 Effectiveness and safety outcomes after 0.18-mg FAi insertion
Full size table

Methods

As available from patient medical records, the following data were collected: sex, age, affected eye(s), medical history, ocular history, time since diagnosis, previous treatments, concomitant treatments, number of recurrences, time to recurrence, intraocular pressure (IOP), central subfield thickness (CST), and visual acuity (VA) as measured by each practitioner. Each retrospective case was conducted in accordance with the tenets of the Declaration of Helsinki and the Health Insurance Portability and Accountability Act of 1996. Consent was requested and obtained from the patients for study inclusion.

Investigators determined recurrence of uveitis according to their individual practice patterns, using criteria such as increase in cellular activity or vitreous haze attributable to NIU-PS, deterioration in visual acuity, increase in macular edema as measured by CST, and/or the need for additional anti-inflammatory medications.

Results

Eighteen eyes diagnosed with non-infectious uveitis and CME were treated by 6 practitioners with the 0.18-mg FAi during active inflammation (Table 1). At baseline, this population had a mean age of 72 years (range: 46 to 93 years), were 53% male, had a mean follow-up of 16.5 months post-FAi (range: 2 to 42.5 months), and had a mean disease duration of 3 years (range: 1 to 19 years) with uncontrolled uveitis before 0.18-mg FAi administration (Table 1). Individual patient narratives and diagnoses are described in detail in the Supplementary Appendix.

All patients were diagnosed with noninfectious uveitis and CME, and for most (14/15 [93%]), a history of cataract or retinal surgery preceded and/or aggravated the diagnosis. Ten patients received their diagnosis prior to cataract or retinal surgery, and 5 patients were diagnosed with post-operative non-infectious uveitis with CME. Of the 15 patients, 8 patients were diagnosed with posterior uveitis, 3 with intermediate uveitis, 2 with panuveitis (1 of these 2 had anterior segment involvement), 1 with pars planitis, and 1 with posterior cyclitis. All patients underwent a diagnostic workup for their uveitis, which included laboratory investigation (Table 1 legend), clinical examination, and ophthalmic imaging, including slit-lamp and dilated fundus examination, optical coherence tomography (OCT), fluorescein angiography, and fundus autofluorescence. One patient had myopic degeneration and posterior vitreous detachment in both eyes, and the left eye had severe pars planitis, leading to chronic and uncontrolled NIU-PS.

Of the 18 eyes in this series, 11 (61%) had 5 or more recurrences of uveitis since initial diagnosis, with an average time to recurrence around 12 weeks (range: 1 to 27). One eye (case #6) had no recurrences before receiving the 0.18-mg FAi (Table 1). The two most common ocular medications used to manage NIU-PS recurrence before treatment with the 0.18-mg FAi were short-acting intravitreal injection (IVI) corticosteroids, including triamcinolone acetonide (56% for each eye) and dexamethasone implant (78% for each eye). Less common IVI medications used in this case series were off-label bevacizumab (1 eye) and off-label methotrexate (3 eyes) (Table 1). Following treatment with the 0.18-mg FAi, all eyes had improvement in VA and decrease in CST as measured by OCT (Table 2).

Of the 18 eyes, 2 were treated with adjunctive intraocular therapy for NIU-PS recurrence following the 0.18-mg FAi: 1 eye (case #13) received a single dexamethasone IVI 7 weeks after the FAi without the need for additional corticosteroid IVI, and another eye (case #3) received ongoing dexamethasone IVI every 17 weeks after the implant (total of 4 dexamethasone IVI), which represented a substantial reduction in IVI corticosteroid treatment frequency (previously every 4 to 6 weeks). Another eye (case #1) required ongoing topical prednisolone for recurrent anterior segment inflammation. Two eyes (case #11) had uveitis recurrence 36 months after 0.18‑mg FAi; this patient then received dexamethasone IVI in both eyes, followed by a second round of 0.18‑mg FAis in both eyes.

Safety events after treatment with the 0.18-mg FAi were tolerable. Only 1 eye from the case series developed persistent IOP elevation after the FAi was injected, and this eye was treated with topical brimonidine tartrate drops; no eyes required surgical intervention for elevated IOP. One eye developed culture-negative endophthalmitis after FAi insertion, and this eye received intravitreal antibiotics. Six weeks after antibiotics were given, the patient’s VA returned to baseline, and the 0.18-mg FAi inhibited uveitis recurrence for more than a year (case #15) (Table 2).

Discussion

Eyes that undergo multiple intraocular surgeries are at risk for inflammation-related sequelae, including CME, proliferative vitreoretinopathy, and chronic NIU-PS. The mainstay of treatment to manage NIU-PS is local corticosteroids administered topically or via peri/intraocular injection [15]. However, patients with chronic uveitis are at increased risk of secondary glaucoma and cataract formation due to prolonged intraocular inflammation and corticosteroid use [16]. Patients with uveitis also tend to undergo cataract surgery at a younger age than those without uveitis [17,18,19,20] and may be at increased risk of postoperative CME and limited visual recovery [21, 22].

There are three FDA-approved IVI FAi dose formulations in the United States, including the high dose 0.59-mg formulation (RETISERT; Bausch + Lomb) indicated for chronic NIU-PS and 2 lower dose formulations, 0.19-mg (ILUVIEN; Alimera Sciences) for diabetic macular edema, and the 0.18-mg FAi (YUTIQ; Alimera Sciences) for chronic NIU‑PS [23]. In phase 3 clinical trials, the 0.18-mg FAi prevented and/or delayed uveitic recurrences, improved VA, and reduced the need for adjunctive therapy among patients with NIU-PS over 36 months [24, 25]. The 0.18-mg FAi is administered in an office setting and delivers a daily dose of 0.2 µg of fluocinolone acetonide [24]. The 0.59-mg FAi, on the other hand, must be surgically implanted [23, 26]. Injection of the 0.18-mg FAi represents an alternative to repeated treatments with shorter-acting corticosteroids, potentially reducing injection-related risks and overall treatment burden, as well as improving long term outcomes by minimizing inflammation recurrences.

As the use of any intraocular corticosteroid may result in IOP elevation, patients should be routinely monitored. Many patients in this case series received intraocular steroid therapy before placement of the 0.18-mg FAi, making the likelihood of an IOP response more predictable. It is hypothesized that the lower dose of fluocinolone (relative to the 0.59-mg implant) and near zero-order kinetics of the long-acting 0.18-mg FAi may be associated with a relatively low propensity for triggering significant increases in IOP [24, 27].

This case series demonstrates real-world experiences and treatment patterns with the 0.18‑mg FAi in eyes with chronic and/or recurrent NIU-PS. In most of these cases, uveitic inflammation was resolved or decreased in intensity for the duration of the FAi lifespan, without the need for additional IVIs (4 eyes required additional steroid IVI post-FAi to help lower inflammation).

In summation, across various surgeons and presentations, the eyes in this series experienced control of NIU-PS and improved vision after treatment with the 0.18 mg FAi, with no new safety signals. Additional studies should enhance our understanding of outcomes with follow up beyond the expected life of the implant.

Conclusion

Eyes with chronic and/or recurrent non-infectious uveitis affecting the posterior segment had sustained resolution of CME and inflammation after receiving the 0.18-mg FAi, with no new adverse effects.

Data availability

All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Abbreviations

CME:

cystoid macular edema

CST:

central subfield thickness

FAi:

fluocinolone acetonide implant

FDA:

Food and Drug Administration

IOP:

intraocular pressure

IVI:

intravitreal injection

NIU-PS:

non-infectious uveitis affecting the posterior segment

OCT:

optical coherence tomography

VA:

visual acuity

References

  1. Chen SC, Sheu SJ (2017) Recent advances in managing and understanding uveitis. F1000Res 6:280. https://doi.org/10.12688/f1000research.10587.1

  2. Suttorp-Schulten MS, Rothova A (1996) The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80(9):844–848

  3. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88(9):1159–1162

  4. Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD (2019) Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol 13:1761–1777

  5. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516

  6. Bajwa A, Osmanzada D, Osmanzada S et al (2015) Epidemiology of uveitis in the Mid-atlantic United States. Clin Ophthalmol 9:889–901

  7. Joltikov KA, Lobo-Chan AM (2021) Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med (Lausanne) 8:695904

  8. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3):491–500

  9. Thorne JE, Suhler E, Skup M et al (2016) Prevalence of noninfectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmol 134(11):1237–1245

  10. Bodaghi B, Cassoux N, Wechsler B et al (2001) Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Med (Baltim) 80(4):263–270

  11. Pavesio C, Heinz C (2022) Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis. Eye (Lond) 36(6):1231–1237

  12. Testi I, Pavesio C (2019) Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis. Ther Deliv 10(10):621–625

  13. YUTIQ (2023) Prescribing information. Alimera Sciences, Inc. https://www.yutiq.com/pi/

  14. Chang PY (2022) Use of fluocinolone acetonide intravitreal implant to manage chronic panuveitis for long-term inflammatory control without interfering with systemic immunity. Digit J Ophthalmol 28(4):119–125

  15. Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG (2019) Update in treatment of uveitic macular edema. Drug Des Devel Ther 13:667–680

  16. Harapriya A, Anthony E (2019) Managing cataract surgery in patients with uveitis. Community Eye Health 31(104):82–83

  17. Schein OD, Cassard SD, Tielsch JM, Gower EW (2012) Cataract surgery among Medicare beneficiaries. Ophthalmic Epidemiol 19(5):257–264

  18. Bajraktari G, Jukić T, Kalauz M, Oroz M, Radolović Bertetić A, Vukojević N (2023) Early and late complications after cataract surgery in patients with uveitis. Med (Kaunas) 59(10):1877

  19. Jevnikar K, Počkar S, Umek L, Rothova A, Valentincic NV (2023) Prognostic factors of cataract surgery in patients with uveitis. Int Ophthalmol 43(12):4605–4612

  20. Chu CJ, Dick AD, Johnston RL, Yang YC, Denniston AK, UK Pseudophakic Macular Edema Study Group (2017) Cataract surgery in uveitis: a multicentre database study. Br J Ophthalmol 101(8):1132–1137

  21. Shaw E, Patel BC (2023) Complicated cataract. StatPearls, vol 4. StatPearls Publishing, Treasure Island (FL)

  22. Bélair ML, Kim SJ, Thorne JE et al (2009) Incidence of cystoid macular edema after cataract surgery in patients with and without uveitis using optical coherence tomography. Am J Ophthalmol 148(1):128–35e2

  23. Gaballa A, Kompella UB, Elgarhy O et al (2021) Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res 11:866–893

  24. Jaffe GJ, Pavesio CE, Study I (2020) Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology 127:1395–1404

  25. Steeples LR, Pockar S, Jones NP, Leal I (2021) Evaluating the safety, efficacy and patient acceptability of intravitreal fluocinolone acetonide (0.2mcg/day) implant in the treatment of non-infectious uveitis affecting the posterior segment. Clin Ophthalmol 15:1433–1442

  26. Jaffe GJ, Lin P, Keenan RT, Ashton P (2016) Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results. Ophthalmology 123:1940–1948

  27. Yang Y, Bailey C, Loewenstein A, Massin P (2015) Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina 35(12):2440–2449

Download references

Acknowledgements

Medical writing assistance was provided by Haley Borusas, PharmD, of Ethis Inc., and supported by Alimera Sciences, Inc.

Funding

Alimera Sciences, Inc. USA participated in the review and funding of the manuscript.

Author information

Authors and Affiliations

  1. Cincinnati Eye Institute, 1945 CEI Drive, Cincinnati, OH, 45242, USA

    Robert A. Sisk

  2. Retina Partners of Florida, Lakeland, FL, USA

    Daniel F. Kiernan

  3. Erie Retinal Surgery, Erie, PA, USA

    David Almeida

  4. NJ Retina, New Providence, NJ, USA

    Anton M. Kolomeyer

  5. Scheie Eye Institute, Department of Ophthalmology, University of Pennsylvania, Philadelphia, PA, USA

    Anton M. Kolomeyer

  6. Retina Vitreous Associates of Florida, St. Petersburg, FL, USA

    David Eichenbaum

  7. Retina Associates of Kentucky, Lexington, KY, USA

    John W. Kitchens

Authors
  1. Robert A. Sisk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel F. Kiernan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anton M. Kolomeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Eichenbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John W. Kitchens
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors reviewed and interpreted their case data and collaborated in the drafting of this manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Robert A. Sisk.

Ethics declarations

Ethics approval and consent to participate

This retrospective case series was in accordance with good clinical practice protocols and adhered to the tenets of the Declaration of Helsinki. Informed verbal and written consent was obtained from the patients for the publication of this report. Sterling IRB determined our series was exempt from IRB review (reference # 12292-RSisk) due to the low-risk nature of the retrospective study.

Consent for publication

Consent was requested and obtained from the patients for study inclusion.

Competing interests

Robert A. Sisk: consultant for AGTC/Beacon, Ascidian, EyePoint, Gyroscope, Iveric Bio, Leica Microsystems, Novartis, Orbit Biomedical, Oxular, and RegenxBio. Daniel F. Kiernan: speaker’s bureau for Alimera, Allergan/AbbVie, Bausch & Lomb, Coherus, EyePoint, Harrow, Mallinckrodt, Novartis, Notal Vision, Physician Recommended Nutraceuticals, and Regeneron. Consultant for Allergan/AbbVie, Bausch + Lomb, Coherus, EyePoint, Mallinckrodt, Physician Recommended Nutraceuticals, and Regeneron. Received grant support from Allergan/ Abbvie, EyePoint, Gyroscope, and Opthea. David Almeida: consultant for Alcon, Alimera, Allergan/AbbVie, Genentech, and Regeneron. Has received financial support (funding, grants, research materials, or in-kind services) from Acylerin, Alcon, Alimera, Allergan/AbbVie, Bausch + Lomb, Bayer, Boehringer Ingelheim, Dutch Ophthalmics, EyePoint, Genentech, Gyroscope, Novartis, Ocugen, Opthea, Regeneron, RegenexBio, Roche, and Samara Vision. Has personal financial interest in Citrus Therapeutics (cofounder), Erie Retina Research (President & CEO), Element: Reading Center (President & CEO), Access for All (Non-profit; chairman of the board), KPeye (President & CEO), React: Research in Advanced Technologies (cofounder & managing partner), and ACT: Applied Clinical Technologies (cofounder and managing partner). Anton M. Kolomeyer: consultant for Alimera, Allergan, Apellis, Biogen, Genentech, Iveric (Astellas), and Regeneron. Speaker for Biogen, Genetech, and Iveric (Astellas). David Eichenbaum: consultant for Alimera, Allergan, Annexon, Appelis, Bausch + Lomb, Coherus, Crinetics, Eyepoint, Genentech, IvericBio, Kodiak, Novartis, Ocuphire, Opthea, Outlook, Ocular Therapeutix, RecensMedical, Regeneron, RegenexBio, ReVive, Samsara, and Vestrum/CorEvitas. Speaker for Allergan, Apellis, Bayer, Genentech, IvericBio, Novartis, and Regeneron. Investigator for 4DMT, Aerie/Alcon, Alexion, Allegenesis, Annexon, Aviceda, Bayer, EyeBio, EyePoint, Gemini, Genentech, Gyroscope, Ionis, IvericBio, Janssen, Kodiak, Mylan, NGM, Janssen, Novartis, Ocular Therapeutix, Opthea, RecensMedical, Regeneron, RegenxBio, ONL, and Unity. Holds equity/ is a stockholder in the Boston Image Reading Center, Janssen, Network Eye, ReVive, and US Retina. Founder of Network Eye. John W. Kitchens: consultant for Alcon, Allergan, Alimera, Apellis, Astellas, Bayer, Biogen, Bausch + Lomb, Genentech, Kodiak Bioscience, Notal Vision, Optos, Oculus, Outlook, Regeneron, Roche, and Zeiss. Speaker for Alcon, Bayer, Genentech, and Regeneron. Owns stock in Regeneron.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sisk, R.A., Kiernan, D.F., Almeida, D. et al. Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients. J Ophthal Inflamm Infect 14, 44 (2024). https://doi.org/10.1186/s12348-024-00427-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12348-024-00427-9

Keywords